Table 1.
The information about the included studies.
| References | Randomized sample size:I/C | Intervention (/once) | Control | Treatment duration (Month) | Cognitive assessment |
|---|---|---|---|---|---|
| Suzanne Craft (20) | 36, 38/30 | 20 IU of Insulin 40 IU of Insulin |
Placebo | 48 M | ADAS-Cog score ADCS-ADL scale score |
| Suzanne Craft (21) | 12/12 | 20 IU of Insulin | Placebo | 4 M | MMSE score |
| Maja Mustapica (22) | 33, 32/26 | 20 IU of Insulin 40 IU of Insulin |
Placebo | 4 M | ADAS-Cog score |
| Amy Claxtona (23) | 36, 38/30 | 20 IU of Insulin 40 IU of Insulin |
Placebo | 4 M | ADAS-Cog score ADCS-ADL scale score |
| José A. Luchsinger (24) | 40/40 | 500 mg Metformin | Placebo | 32 M | MMSE score ADAS-Cog score |
| Michael Rosenbloom (25) | 19/16 | 20 IU of Insulin | Placebo | 6 M | ADAS-Cog score |
| David S. Geldmacher (26) | 15/14 | 15 mg Pioglitazone | Placebo | 18 M | ADAS-Cog score |
| Haruo Hanyu (27) | 15/17 | 15 mg−30 mg Pioglitazone | Placebo | 6 M | MMSE score |
| TomohikoSato (28) | 21/21 | 15 mg−30 mg Pioglitazone | Placebo | 6 M | MMSE score ADAS-Cog score |
| Risner (29) | 127,130/122 | 2 mg Rosiglitazone 4 mg Rosiglitazone 8 mg Rosiglitazone |
Placebo | 6 M | ADAS-Cog score |
| C. Harrington (30) | 473, 459/461 | 2 mg Rosiglitazone 8 mg Rosiglitazone |
Placebo | 12 M | ADAS-Cog score |
| Michael Gold (31) | 162, 156/159 | 2 mg Rosiglitazone 8 mg Rosiglitazone |
Placebo | 6 M | ADAS-Cog score |
| Michael C. Irizarrya (32) | 733/856 | Rosiglitazone | Placebo | 6 M | ADAS-Cog score |
| Qiang Li (33) | 24/21 | 0.6 mg−1.8 mg GLP-1 | Placebo | 3 M | MMSE score |
| Roger J. Mullins (34) | 11/10 | GLP-1 | Placebo | 18 M | MMSE score ADAS-cog score |
| Jujun Xue (35) | 30/30 | 100 mg Sitagliptin | Placebo | 6 M | MMSE score |
I/C, Intervention/Control; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive section; ADCS-ADL, Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale; MMSE, Mini-mental State Examination; GLP-1Glucagon-like Peptide-1.